Bayer Corporation, Johnson and Johnson Pharmaceutical Research and…
Published by Food and Drug Administration News May 31st, 2008 in UncategorizedResults from a pivotal Phase III clinical trial presented today demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in …